Senators call for FDA nanotech program
This article was originally published in The Rose Sheet
Executive Summary
Bill introduced by Sens. Mark Pryor (D-Ark.) and Benjamin L. Cardin (D-Md.) would establish an FDA program "to assess the health and safety implications of nanotechnology in everyday products and develop best practices for companies that employ nanotechnology." In a Jan. 21 release, Pryor states: "As these products are developed and used, we must understand any potential risks to human health, safety or the environment." He maintains that FDA's involvement "will help ensure public safety and confidence in the marketplace" and support firms using nano-sized materials. Legislation would authorize $25 million annually from 2011 through 2015 to fund the program. FDA already has facilities in place to conduct studies required under the bill, including the National Center for Toxicological Research in Arkansas and its consolidated headquarters in Maryland, Pryor notes. In August 2009, the Project on Emerging Nanotechnologies had netted more than 600 health and fitness products - including cosmetics and personal-care items - in its database of nanotechnology-containing consumer goods marketed worldwide (1"The Rose Sheet" Sept. 7, 2009)
You may also be interested in...
Health Products Lead Rapidly Expanding Nanotechnology Product List
Health & fitness products including cosmetics and personal-care items dominate the landscape of nano-engineered consumer goods, according to the Project on Emerging Nanotechnologies, overseen by the Woodrow Wilson International Center for Scholars
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.